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Main text:  
Despite the excellent overall survival in childhood acute lymphoblastic leukemia (ALL), 
central nervous system (CNS) disease continues to pose challenges. Currently, only 3-5% 
children with ALL present with cytological evidence of CNS involvement [1], however CNS-
directed therapy is essential for cure, and the majority of CNS relapses occur in children who 
had negative CNS cytology at diagnosis [2]. This implies that the frequency of patients with 
CNS involvement may be higher than currently detected. There is a clear need for improving 
diagnostic accuracy of CNS involvement. Leukemic cells, being clonal in origin, carry VDJ 
gene rearrangements unique to individual patients. Using allele-specific oligonucleotides 
(ASO) primers TaqMan qPCR accurately estimates minimal residual disease (MRD) and 
predicts bone marrow relapse. [3]. However, bone marrow MRD status does not predict the 
risk of CNS relapse.  
We investigated if qPCR could identify patients with submicroscopic levels of CNS 
involvement at diagnosis and to track therapy response. Our research questions were: i) can 
amplifiable DNA be extracted from leftover cerebrospinal fluid (CSF) samples obtained for 
routine CSF cytology? ii) Can allele-specific PCR primers designed for bone marrow MRD 
detect leukemic in the CNS? Iii) Is CSF qPCR able to track treatment response in the CNS? 
The study was approved by the West of Scotland Research Ethics Committee (WoSREC 
reference: 09/SO703/77). Between July 2011 and July 2014, children (1-18 years old) 
diagnosed with ALL at the Royal Hospital for Sick Children, Glasgow were enrolled in the 
study. Diagnostic and follow-up CSF samples during induction therapy were collected. DNA 
was extracted using Qiagen QIAmp DNA Micro kit and quantified using TaqMan Real-Time 
qPCR assay for Albumin [4]. ASO primers were designed at the Glasgow MRD laboratory 
according to Biomed-II guidelines [5]. 
During the study period, 57 patients were enrolled. Out of these 19 were excluded from 
analysis (see supplementary table 1 for details). This left samples from 38 patients for 
analysis (31 patients with CNS-1 disease (no blasts in CSF cytology), 5 with TLP+ve 
(traumatic lumbar puncture with identifiable blasts) and 2 with TLP-ve (traumatic lumbar 
puncture without blasts)) (supplementary table 2 and 3).  
Real-time qPCR revealed detectable leukemic DNA in 15/38 patients (39.5%) (designated 
qPCR positive). Among these, 11 were CNS-1 patients and 4 were TLP+ve patients. 1/5 
TLP+ve and 2/2 TLP-ve patients were CSF qPCR negative. Comparison of CSF qPCR 
positive vs. negative patients showed an association with a higher WCC (mean 26.6 x 109/l 
vs 19.4 x 109/l) and high-risk cytogenetics (p=0.04) – factors recognized as high-risk for CNS 
relapse. Three out of 4 patients with T-ALL were CSF qPCR positive (table 1). 
Next, serial samples from 18 patients during the induction phase of treatment were analysed 
(11 patients were CSF qPCR negative and 7 were CSF qPCR positive at diagnosis). All 
patients were CSF qPCR negative on day 29 (end of induction). Two day 8 samples (patient 
#22 and #37), and one day 15 sample (patient #37) were CSF qPCR positive. (figure 1). 
Overall, these results indicate that qPCR positive disease is rapidly cleared from the CSF 
during induction.  
 Twenty patients had sufficient template DNA to test two primer/probe sets, 13 patients were 
negative and 4 patients were positive with both sets, whilst 3 patients were positive with one 
set but negative with the other (supplementary figure 1). 
CSF qPCR positivity at diagnosis was not associated with BM MRD risk status at the end of 
induction. In this small study, no CNS relapses were seen during the period of follow up (71 
± 10 months, median ±SD). One CSF qPCR negative patient suffered isolated BM relapse at 
4-years (Supplementary table 3). 
Our findings indicate that the use of qPCR detects occult CNS involvement in more than 
one-third of children with acute lymphoblastic leukemia. This is consistent with other newer 
methods such as flow-cytometry [6]. However, this technique also has important limitations. 
Firstly, 19/57 (33%) patient samples could not be used for ASO qPCR testing due to lack of 
amplifiable DNA or suitable primers. Some of these patients may represent true negative 
cases with no circulating blasts in the CSF, alternatively the small volume of CSF obtained 
may have yielded inadequate DNA. Secondly, 1/5 TLP+ patients was negative by qPCR 
although this may reflect either false positive cytology or false negative qPCR. Thirdly, 3/20 
patients had discordant results when testing two primer/probe sets. This is most likely to be 
due to differing sensitivity of the two assays. Alternatively, there could be subclonal selection 
of cells bearing only one of the two VDJ rearrangements in the CNS. A body of experimental 
evidence from our previous work [7], and others [8] argue against this. Finally, the real power 
of developing biomarkers of CNS leukemia would be the ability to track response to 
treatment within the CNS compartment. Thus, an ideal test should be able to separate 
patients into rapid and slow responders, with subsequent follow-up needed to confirm that 
this has prognostic significance. In our study, all patient samples became negative by the 
end of induction chemotherapy, suggesting that it is too insensitive for disease response 
assessment. 
Given these limitations, qPCR of CSF is unlikely to be clinically useful. Alternative strategies 
such as flow-cytometry or NGS still rely on detection of circulating cells within the CSF. 
Historical reports of autopsies [9] and our previous data [10] show that leukemic blasts are 
often embedded in the meninges and not present in a free-floating state. Future research 
into soluble biomarkers released by leukemic cells into circulating CSF might be the best 
way forward.  
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Figure
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Figure 1: qPCR positivity of representative set of patients at diagnosis and during induction period. 
Time points: Days post diagnosis, open circles = qPCR negative, closed circles = qPCR positive, cross= 
No amplifiable DNA, open box = no leftover samples available. 
Figure Legend
 
       
 
Variable Category QPCR+ve QPCR-ve 
 
 
  
n % n % 
  
15 39.5% 23 60.5% p-value*  
Age at diagnosis  <10 year 12 39% 19 61% 0.839  
 
 >10 years 3 43% 4 57% 
 
 
Sex  Male 12 50% 12 50% 0.101  
 
 Female 3 21% 11 79% 
 
 
Immunophenotype  BCP-ALL 12 35% 22 65% 0.280  
 
 T-ALL 3 75% 1 25% 
 
 
WCC  <10 4 21% 15 79% 0.043  
 
 10-50 9 64.3% 5 35.7% 
 
 
  >50 2 40% 3 60%   
CNS status  CNS-1 11 35% 20 65% 0.084  
 
 TLP+ 4 80% 1 20% 
 
 
 
 TLP- 0 0% 2 100% 
 
 
Cytogenetic risk  Low risk 7 28% 18 72% 0.04  
 
 High risk 3 100% 0 0% 
 
 
 
 Others 5 50% 5 50% 
 
 
Day 29 MRD  MRD risk 8 50% 8 50% 0.258  
 
 Low risk 7 35% 15 65% 
 
 
 
 
Table 1
Table 1 Comparison between CSF qPCR +ve and qPCR –ve patients 
*calculated using Chi squared test 
cytogenetic risk: 
Low risk  t(12;21), High hyperdiploid 
High risk t(9;22), MLL-rearranged 
Others t(7;9), del 12p, t(9;18), complex cytogenetics of uncertain origin 
 
 
Table Legend 1
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Reason for exclusion from analysis Number of patients 
Total number of patients enrolled 57 
No leftover CSF for analysis -4 
Poor quality DNA (albumin amplification >38 CT cycles). -7 
Excluded due to unavailability of suitable primers -5 
qPCR assays excluded due to technical error during the PCR run (with 
insufficient DNA available to repeat) 
-3 
Total analysed samples 38 
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Supplementary table 1: Reasons for exclusion of patients from final analysis 
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Characteristic   no.  (%) 
Age (years) <10 44  77.1% 
 
>10 13  22.9% 
Sex Male 38  66.7% 
 
Female 19  33.3% 
Immunophenotype BCP-ALL 51 89.4% 
 
T-ALL 6  10.6% 
Cytogenetics t(9;22) 1  1.9% 
 
MLL-rearranged 3  5.6% 
 
t(12;21) 10  18.5% 
  High Hyperdiploid 21  36.8% 
WCC <10 28  49.1% 
(x 10
9
/L) 10-50 22  38.5% 
 
>50 7  13% 
CNS disease CNS1 50 87.7% 
 
TLP- 3  5.2% 
 
TLP+ 4  7.0% 
 
CNS-3 0 0% 
Anaemia Hb<8g/dl 30 52.6% 
 
Hb>8g/dl 27 47.4% 
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Supplementary table 2: Demographic and clinical characteristics of enrolled patients 
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Supplementary table 3: 
ID Age  S
e
x 
Diagnosis Cytogenetics CNS 
status 
WCC 
/ul 
Day 29 
MRD 
CSF 
qPC
R 
Outcome Follow 
up 
(mnths) 
#1 7.9 F BCP-ALL High hyperdiploid 1 1 High risk No CCR* 75 
#2 17.1 M BCP-ALL t(9;22) 1 98.49 High risk Yes CCR 71 
#3 11.1 F BCP-ALL dic(7;9)  
Unbalanced 
translocation p7 and 
p9  
1 23.8 High risk No CCR 74 
#4 2.8 F BCP-ALL High hyperdiploid 1 9.1 Risk No CCR 51 
#5 6.4 M BCP-ALL DER (1,16), DER 
3,+9, DEL12p 
TLP 
+ve 
3.6 Low risk No CCR 85 
#6 15.0 F BCP-ALL t(9;18) TLP -
ve 
167.5 High risk No CCR 81 
#7 2.7 M BCP-ALL High hyperdiploid 1 82 Risk No CCR 71 
#8 6.2 F BCP-ALL High hyperdiploid 1 11.7 Risk No CCR 54 
#9 3.9 M BCP-ALL High hyperdiploid 1 33.2 Risk Yes CCR 60 
#10 14.2 M T-ALL Normal Karyotype 1 6.4 High risk No CCR 87 
#11 1.1 M BCP-ALL MLL rearranged 1 3.2 Low risk Yes CCR 55 
#12 2.4 M BCP-ALL Normal karyotype 1 11.1 Low risk Yes CCR 83 
#13 10.3 M BCP-ALL Normal karyotype 1 1.8 High risk No CCR 75 
#14 2.5 M BCP-ALL High hyperdiploid 1 2 Low risk No CCR 65 
#15 3.8 M BCP-ALL t(12;21) 1 10.6 Low risk No CCR 85 
#16 6.1 M BCP-ALL High hyperdiploid 1 2 Low risk Yes CCR 62 
#17 4.9 M BCP-ALL t(12;21) 1 52 Low risk No CCR 75 
#18 9.1 M T-ALL Normal Karyotype 1 36.4 High risk Yes CCR 73 
#19 1.1 M BCP-ALL High hyperdiploid 1 17.6 Risk No CCR 69 
#20 4.9 M BCP-ALL High hyperdiploid 1 6.9 Risk No CCR 65 
#21 1.7 F BCP-ALL High hyperdiploid 1 2.7 Risk Yes CCR 62 
#22 2.7 M BCP-ALL High hyperdiploid TLP+
ve 
10.8 Low risk Yes CCR 81 
#23 3.5 M BCP-ALL t(12;21) TLP+
ve 
46 Low risk Yes CCR 80 
#24 2.3 F BCP-ALL High hyperdiploid 1 3.2 Risk No CCR 51 
#25 5.5 F BCP-ALL High hyperdiploid 1 4.2 MRD 
Risk 
No Died 72 
#26 5.4 F BCP-ALL Normal Karyotype 1 28 Low risk Yes CCR 80 
#27 6.0 F BCP-ALL High hyperdiploid 1 1.1 Low risk No CCR 72 
#28 2.5 F BCP-ALL t(12;21) 1 19.1 MRD 
risk 
No CCR 71 
#29 3.7 M BCP-ALL t(12;21) 1 4.9 MRD 
Risk 
No CCR 52 
#30 2.6 F BCP-ALL High hyperdiploid 1 6.2 Low risk Yes CCR 69 
#31 5.4 M BCP-ALL t(12;21) 1 5.3 Low risk No CCR 85 
#32 2.1 M T-ALL Normal Karyotype 1 56.5 Low 
Risk 
Yes CCR 69 
#33 3.3 M BCP-ALL High hyperdiploid 1 1.7 Risk No CCR 69 
#34 13.9 F T-ALL NA 1 28 Risk Yes CCR 62 
#35 3.2 F BCP-ALL High hyperdiploid TLP-
ve 
3.1 Low risk No CCR 53 
#36 10.8 M BCP-ALL High hyperdiploid TLP 
+ve 
13.6 High risk Yes CCR 73 
#37 2.3 M BCP-ALL 11q23 TLP+
ve 
23.4 High risk Yes CCR 81 
#38 3.5 M BCP-ALL NA 1 8.1 Low 
Risk 
No CCR 66 
Supplementary table 3: Patient characteristics and CSF qPCR status. CNS status is based on CSF 
cytospin analysis (CNS-1= Leukocytes <5/ul, no identifiable blasts, CNS-2 = >5 leukocytes with 
Supplementary Materials
identifiable blasts, CNS-3 = > 5 blasts/ul, TLP +ve = traumatic lumbar puncture with blasts, TLP -ve 
= traumatic lumbar puncture without blasts). MRD risk based on Molecular monitoring of minimal 
residual disease, CCR= Complete clinical remission, NA=Not available. 
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Supplementary Figure 1: qPCR amplification plots showing (a) amplification by two PCR 
targets, (b) no amplification seen in CSF DNA (c) amplification in 1 out of 2 PCR targets. 
MNC=mononuclear cell DNA from healthy controls used as a negative control. 
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